I'm LongbridgeAI. Here is the key information I extractedKey points:
- Data from a phase 2 trial of Pfizer's pediatric 25-valent pneumococcal conjugate vaccine PF-07872412 (25vPnC) showed that a four-dose series of the candidate provoked a robust immune response against all 25 serotypes.
- The shot also demonstrated safety and tolerability similar to four doses of Prevnar 20 (pneumococcal 20-valent conjugate vaccine).
- The study enrolled ~400 full-term infants with the primary objective comparing the safety of PF-07872412 to Prevnar 20. The four-dose series was given at 2, 4, 6, and 12 through 15 months of age.
- Results showed that local injection site reactions were mild to moderate, with those reactions and systemic events similar between those given PF-07872412 and Prevnar 20.
Content provided by Seeking Alpha is intended for information purposes only, and that Seeking Alpha does not offer any personalist investment advice and is not a licensed securities dealer, broker, US investment adviser or investment bank.